Biomerica (NASDAQ:BMRA) Share Price Passes Below 200 Day Moving Average – Time to Sell?

Biomerica, Inc. (NASDAQ:BMRA)’s stock price passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $2.52 and traded as low as $2.10. Biomerica shares last traded at $2.13, with a volume of 11,521 shares changing hands.

Biomerica Trading Down 2.7%

The firm has a 50-day simple moving average of $2.26 and a two-hundred day simple moving average of $2.52. The company has a market capitalization of $6.43 million, a price-to-earnings ratio of -2.29 and a beta of 0.21.

Biomerica (NASDAQ:BMRA) last issued its quarterly earnings data on Wednesday, January 14th. The company reported ($0.45) earnings per share (EPS) for the quarter. Biomerica had a negative net margin of 90.29% and a negative return on equity of 83.73%. The company had revenue of $1.21 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Biomerica stock. DRW Securities LLC grew its stake in Biomerica, Inc. (NASDAQ:BMRA) by 62.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,925 shares of the company’s stock after purchasing an additional 6,533 shares during the period. DRW Securities LLC owned about 0.56% of Biomerica worth $43,000 at the end of the most recent quarter. 22.28% of the stock is owned by institutional investors and hedge funds.

Biomerica Company Profile

Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.